Veeva stelt de sector in staat om regelgevingsprocessen te stroomlijnen en gelijke tred te houden met veranderende regelgeving zoals IDMP
BARCELONA, Spanje – (BUSINESS WIRE) – Veeva Systems (NYSE: VEEV) heeft vandaag aangekondigd dat meer dan 250 organisaties Veeva Vault RIM applicaties gebruiken voor end-to-end reguleringsinformatiebeheer. Een groeiend aantal opkomende biotechbedrijven en grote ondernemingen, waaronder 12 van de 20 grootste farmaceutische bedrijven ter wereld, moderniseren de planning, tracking en publicatie van indieningen om de veranderende regelgeving voor te blijven, waaronder de ISO IDMP-normen.
“Het stroomlijnen van regelgevingsprocessen is een strategische prioriteit om een efficiënte planning en uitvoering van indiening te ondersteunen en om medicijnen sneller bij patiënten te krijgen”, zegt Dominique Lagrave, hoofd wereldwijde regelgevende activiteiten bij Amgen. “Veeva Vault RIM zal regelgevingsprocessen verenigen en de zichtbaarheid bieden die we nodig hebben om snellere, beter geïnformeerde beslissingen te nemen.”
More Than 250 Companies Transform Regulatory with Veeva Vault RIM Applications
Veeva enables industry to streamline regulatory processes and keep up with changing regulations like IDMP
BARCELONA, Spain–(BUSINESS WIRE)– Veeva Systems (NYSE: VEEV) today announced that more than 250 organizations are using Veeva Vault RIM applications for end-to-end regulatory information management. A growing number of emerging biotechs and enterprise companies, including 12 of the top 20 global pharmaceutical companies, are modernizing submission planning, tracking, and publishing to stay ahead of evolving regulations, including the ISO IDMP standards.
“Streamlining regulatory processes is a strategic priority to support efficient submission planning and execution and get medicines to patients faster,” said Dominique Lagrave, head, global regulatory operations at Amgen. “Veeva Vault RIM will unify regulatory processes and deliver the visibility we need to make faster, more informed decisions.”
Life sciences companies of all sizes are rapidly adopting Vault RIM applications to simplify management for product registrations, submission documents, published dossiers, and health authority interactions. Vault RIM removes the reliance on spreadsheets and manual processes so regulatory teams can get the right information to the right person at the right time.
Organizations are leveraging Vault Registrations to support IDMP standards with new entities to better track, manage, and link registered product data. Users can also get a complete view into IDMP data sets based on a product’s current registered details and capture IDMP elements throughout the regulatory process. Now regulatory teams can simplify IDMP implementation for improved quality and compliance.
“More companies are partnering with Veeva to keep pace with changing regulations and bring products to market faster,” said John Lawrie, vice president, Veeva Vault RIM. “Veeva Vault RIM delivers the scale to author and publish thousands of change requests and the innovation to seamlessly manage regulations like IDMP.”
The Veeva Vault RIM Suite includes Vault Registrations, Vault Submissions, Vault Submissions Publishing, and Vault Submissions Archive for unified RIM capabilities on one cloud platform. Vault RIM is part of Veeva Development Cloud, a unified suite of applications for clinical, regulatory, quality, and safety to help organizations drive business processes across R&D and manufacturing.
Watch on-demand Veeva R&D and Quality Summit sessions at veeva.com/Summit to learn how leading companies partner with Veeva to transform regulatory information management.
For more on Veeva Vault RIM, visit: veeva.com/RIM
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow @veeva_eu on Twitter: twitter.com/veeva_eu
Like Veeva on Facebook: facebook.com/veevasystems
About Veeva Systems
Veeva Systems Inc. is the leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 950 customers, ranging from the world’s largest pharmaceutical companies to emerging biotechs. Veeva is headquartered in the San Francisco Bay Area, with offices throughout North America, Europe, Asia, and Latin America. For more information, visit veeva.com/eu.
This release contains forward-looking statements, including the market demand for and acceptance of Veeva’s products and services, the results from use of Veeva’s products and services, and general business conditions (including the on-going impact of COVID-19), particularly within the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the company’s filing on Form 10-Q for the period ended October 31, 2020. This is available on the company’s website at veeva.com under the Investors section and on the SEC’s website at sec.gov. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.